Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.

Oncogene - 18 Feb 2016

Whang Y M, Park S I, Trenary I A, Egnatchik R A, Fessel J P, Kaufman J M, Carbone D P, Young J D

Abstract excerpt

The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30% of patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate-activated protein kinase (AMPK) signaling confers sensitivity to metabolic inhibition or stress-induced mitochondrial insults. We tested the hypothesis that loss of LKB1 sensitizes NSCLC cells to energetic stress induced by treatment with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Energy Metabolism

Share to Erlotinib Hydrochloride

Share to Gene Knockdown Techniques

Share to Mice, Nude

Share to RNA, Small Interfering

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26119936
DOI: 10.1038/onc.2015.140
PMCID: PMC4486321

Genes

STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.PMID 26119936Read ↗

Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Semantic proximity Read ↗

Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado.Semantic proximity Read ↗

LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.Semantic proximity Read ↗

LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivatedSemantic proximity Read ↗

Unravelling the connection between metabolism and tumorigenesis through studies of the liver kinase B1 tumour suppressorSemantic proximity Read ↗

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact.Semantic proximity Read ↗

Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approachSemantic proximity Read ↗

Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.Semantic proximity Read ↗

LKB1-AMPK axis revisited.Semantic proximity Read ↗

Synthetic lethality targeting LKB1 mutant and EGFR wild type human non-small cell lung cancer cells by glucose starvation and SGLT2 inhibitionSemantic proximity Read ↗

Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC.Semantic proximity Read ↗

Canagliflozin and Brusatol Synergize against LKB1-KEAP1 Co-Mutant NSCLC through AKT Suppression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.